Recruiting

PMF with MHT

Sponsor:

Mayo Clinic

Code:

NCT07242391

Conditions

Menopause

Left Ventricular Dysfunction

Eligibility Criteria

Sex: Female

Age: 45 - 60

Healthy Volunteers: Not accepted

Interventions

Menopausal Hormone Therapy

Study Details

Brief summary:

The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT.

Conditions

Menopause

Left Ventricular Dysfunction

Study ID

NCT07242391

Start date

Aug 26, 2026

Status verified date

Aug, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Dec, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 45 - 60

Healthy Volunteers: Not accepted

Inclusion Criteria

• >45-60< years of age

Exclusion Criteria

  • Male sex
  • Females between STRAW+10 stages -5 and 0
  • PMF in STRAW+10 stage +2
  • PMF using oral hormone therapy
  • Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy)
  • Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction
  • Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI.
  • Cardiovascular medications is also an exclusion criterion which includes those acting on the renin-angiotensin-aldosterone axis, adrenergic receptor antagonists, diuretics, nitrates, and calcium channel antagonists. Other medications will be evaluated on an individual basis by the PI.
  • Pregnancy
  • COPD
  • Diabetes
  • CKD
  • Raynaud's phenomenon
  • Sleep disorders
  • Shift workers
  • BMI ≥40.0kg/m2
  • Use of nicotine-containing products within the two years preceding study visits
  • Active cancer treatment

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Arms

Post-menopausal females using menopausal hormone therapy

Post menopausal females taking a clinically prescribed menopausal hormone therapy (i.e. pill, patch, etc.)

Post-menopausal females not using menopausal hormone therapy

Interventions

Menopausal Hormone Therapy

Taken in accordance with standard clinical practice, administered for a minimum duration of eight weeks.

Primary outcome measure

  • Left ventricular stroke volume [ Time Frame: Baseline ]

Central Contacts and Locations

Central contacts

Joshua Bock, Ph.D.

507-422-0768bock.joshua@mayo.edu

Locations

Mayo Clinic in Rochester

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Joshua Bock, PhD

(507) 422-0768bock.joshua@mayo.edu

Principal Investigator:

Joshua Bock, PhD

More Information

Sponsor

Mayo Clinic

Last update posted

Aug 27, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-14. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-08-27. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.